Tuesday, September 29, 2009

Keryx Biopharmceuticals Announce Phase 2 Study of Single-Agent Cancer Treatment

RTTnews.com announced today that Keryx Biopharmaceuticals Inc. has announced updated clinical results from a Phase 2 study of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single-agent treatment for advanced metastatic renal cell carcinoma or RCC.

Keryx Biopharma Announces Updated Clinical Results From Phase 2 Study Of KRX-0401 - Quick Facts

Share this article with your social network, just click below to share now!

No comments :

Post a Comment